Dementia Big
Bill Gates has today announced a $50 million investment into the Dementia Discovery Fund, motivated by personal experience of Alzheimer’s disease in his family.
http://ift.tt/2yWGY8b
Dementia Big
Bill Gates has today announced a $50 million investment into the Dementia Discovery Fund, motivated by personal experience of Alzheimer’s disease in his family.
A memory complaint, also called Subjective Cognitive Decline (SCD), is a subjective disorder that appears to be relatively common, especially in elderly persons. The reports of its prevalence in various populations range from approximately 10% to as high as 88%, although it is generally thought that the prevalence of everyday memory problems lie within the range of 25% to 50%. It has been suggested that SCD may be an indication of cognitive decline at a very early stage of a neurodegenerative disease (i.e. preclinical stage of Alzheimer’s disease) that is undetectable by standard testing instruments. SCD may represent the first symptomatic manifestation of Alzheimer’s disease in individuals with unimpaired performance on cognitive tests.
from Dementia Big http://ift.tt/2zFuvmo via alcoholic dementia
Dementia Big
A memory complaint, also called Subjective Cognitive Decline (SCD), is a subjective disorder that appears to be relatively common, especially in elderly persons. The reports of its prevalence in various populations range from approximately 10% to as high as 88%, although it is generally thought that the prevalence of everyday memory problems lie within the range of 25% to 50%. It has been suggested that SCD may be an indication of cognitive decline at a very early stage of a neurodegenerative disease (i.e. preclinical stage of Alzheimer’s disease) that is undetectable by standard testing instruments. SCD may represent the first symptomatic manifestation of Alzheimer’s disease in individuals with unimpaired performance on cognitive tests.
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient’s sense of smell to treat Alzheimer’s disease before it ever develops. Having an impaired sense of smell is recognized as one of the early signs of cognitive decline, before the clinical onset of Alzheimer’s disease. The researchers at CUMC and NYSPI have found a way to use that effect to determine if patients with mild cognitive impairment may respond to cholinesterase inhibitor drugs to treat Alzheimer’s disease.
from Dementia Big http://ift.tt/2iMwrl8 via alcoholic dementia
Dementia Big
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient’s sense of smell to treat Alzheimer’s disease before it ever develops. Having an impaired sense of smell is recognized as one of the early signs of cognitive decline, before the clinical onset of Alzheimer’s disease. The researchers at CUMC and NYSPI have found a way to use that effect to determine if patients with mild cognitive impairment may respond to cholinesterase inhibitor drugs to treat Alzheimer’s disease.
Disordered breathing during sleep is linked to a key hallmark of Alzheimer’s disease, according to new research.
Dementia Big
Disordered breathing during sleep is linked to a key hallmark of Alzheimer’s disease, according to new research.